Details of Disease

General Information of Disease (ID: DISQR5TD)

• Disease Name: Overactive bladder
• Synonyms: overactive bladder; overactive bladder (disease)
• Disease Class: GC50: Functional bladder disorder
• Definition: Symptom of overactive detrusor muscle of the urinary bladder that contracts with abnormally high frequency and urgency. Overactive bladder is characterized by the frequent feeling of needing to urinate during the day, during the night, or both. urinary incontinence may or may not be present.
• Disease Hierarchy:
  DISTVIQI: Bladder disease
  DISQR5TD: Overactive bladder
• ICD Code:
  ICD-11: ICD-11: GC50.0
  ICD-10: ICD-10: N32.8
  ICD-9: ICD-9: 596.51
  Expand ICD-11: 'GC50.0
  Expand ICD-10: 'N32.8
  Expand ICD-9: 596.51
• Disease Identifiers:
  MONDO ID: MONDO_0006624
  MESH ID: D053201
  UMLS CUI: C0878773
  MedGen ID: 168058
  SNOMED CT ID: 786457000

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 10 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Darifenacin	DMWXLYZ	Approved	Small molecular drug	[1]
Fesoterodine fumarate	DM13495	Approved	Small molecular drug	[2]
Manganese Chloride	DMEO4VU	Approved	Small molecular drug	[3]
Manganese Chloride Tetrahydrate	DMYR643	Approved	Small molecular drug	[3]
Manganese Sulfate	DM6QAS0	Approved	Small molecular drug	[3]
Mirabegron	DMS1GYT	Approved	Small molecular drug	[4]
Solifenacin	DMG592Q	Approved	Small molecular drug	[5]
Tolterodine	DMSHPW8	Approved	Small molecular drug	[3]
Trospium	DMX6RTG	Approved	Small molecular drug	[6]
Vibegron	DMFR201	Approved	NA	[7]

This Disease is Treated as An Indication in 11 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Gefapixant	DM4GWL7	Phase 3	NA	[8]
THVD-201	DM3PA8H	Phase 3	NA	[9]
AGN-214868	DMAO869	Phase 2	NA	[10]
ASP-3652	DM4KTN6	Phase 2	NA	[11]
SMP-986	DMTJOQX	Phase 2	Small molecular drug	[12]
Tarafenacin	DMDB4EJ	Phase 2	Small molecular drug	[13]
URO-902	DMF5794	Phase 2	Gene therapy	[14]
XEN-D0501	DMG7PDY	Phase 2	NA	[15]
HMaxi-K	DMDO6JP	Phase 1	NA	[16]
KUC-7483	DMTFWLE	Phase 1	NA	[17]
MCP-202	DM65B7G	Phase 1	NA	[18]

This Disease is Treated as An Indication in 9 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
JTS-653	DM35CQ4	Discontinued in Phase 2	NA	[19]
PSD-506	DMT0KB1	Discontinued in Phase 2	NA	[20]
TA-5538	DMBZG2Y	Discontinued in Phase 2	NA	[21]
TRK-130	DMB4I82	Discontinued in Phase 2	NA	[22]
ZD-0947	DMS95DX	Discontinued in Phase 2	Small molecular drug	[23]
R-701	DMF3A6H	Discontinued in Phase 1	NA	[24]
TAK-259	DM118QU	Discontinued in Phase 1	NA	[25]
TD-6301	DMJ2S4U	Discontinued in Phase 1	NA	[26]
R-1554	DM8XBKG	Terminated	NA	[28]

This Disease is Treated as An Indication in 1 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
URG-302	DMZUSTR	Preclinical	NA	[27]

This Disease is Treated as An Indication in 7 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AE-9C90CB	DMANEH2	Investigative	NA	[29]
Copper catalyst-based agent	DMSGDGR	Investigative	NA	[30]
NS-13001	DMLUCL0	Investigative	NA	[30]
REC-0436	DM625MW	Investigative	NA	[30]
REC-1819	DMAIVGS	Investigative	NA	[30]
TBDT	DMVNU9K	Investigative	NA	[30]
TD-9594	DML1A8S	Investigative	NA	[30]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 11 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ADCYAP1	TTW4LYC	Strong	Therapeutic	[31]
ADRB3	TTMXGCW	Strong	Biomarker	[32]
BDKRB1	TTG5QIA	Strong	Biomarker	[33]
BRD1	TTT09OB	Strong	Biomarker	[34]
EDN1	TTJR60Z	Strong	Biomarker	[35]
GJA1	TT4F7SL	Strong	Biomarker	[36]
GJA5	TTFQKZ7	Strong	Biomarker	[36]
NGF	TTDN3LF	Strong	Biomarker	[37]
NQO1	TT8XK6L	Strong	Therapeutic	[38]
NRG1	TTEH395	Strong	Therapeutic	[39]
TRPA1	TTELV3W	Definitive	Therapeutic	[40]

This Disease Is Related to 1 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC17A9	DT9BI8W	Strong	Altered Expression	[41]

This Disease Is Related to 6 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
RO60	OTLGM5A8	moderate	Biomarker	[42]
MDFIC	OTSRYBWZ	Strong	Biomarker	[43]
MYO5A	OTMWLP3E	Strong	Altered Expression	[41]
OPN1MW	OTPJ7LX4	Strong	Biomarker	[44]
SLC2A4RG	OTW3LX8D	Strong	Genetic Variation	[45]
SUFU	OT0IRYG1	Strong	Biomarker	[46]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 321).
• [2] 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7445).
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7483).
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7480).
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [8] ClinicalTrials.gov (NCT02477709) A Study to Assess the Tolerability of a Single Dose of AF-219 in Subjects With Idiopathic Pulmonary Fibrosis (IPF).
• [9] ClinicalTrials.gov (NCT02485067) Clinical Study to Assess the Efficacy and Safety of THVD-201 in Patients With OAB.
• [10] ClinicalTrials.gov (NCT01678924) A Safety and Efficacy Study of AGN-214868 in Patients With Postherpetic Neuralgia. U.S. National Institutes of Health.
• [11] ClinicalTrials.gov (NCT01613586) A Randomized Study Comparing Placebo and ASP3652 in the Treatment of Women With Bladder Pain Syndrome / Interstitial Cystitis (BPS/IC). U.S. National Institutes of Health.
• [12] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022820)
• [13] ClinicalTrials.gov (NCT01458197) A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder.. U.S. National Institutes of Health.
• [14] ClinicalTrials.gov (NCT04211831) An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of URO-902 in Subjects With Overactive Bladder and Urge Urinary Incontinence. U.S.National Institutes of Health.
• [15] ClinicalTrials.gov (NCT02233699) A Study to Assess the Efficacy of XEN-D0501 in Reducing the Cough Frequency in Patients With Chronic Idiopathic Cough. U.S. National Institutes of Health.
• [16] ClinicalTrials.gov (NCT01870037) Phase 1 Study in Subjects With OAB Assessing the Safety and Activity of 2 Doses of hMaxi-K Gene Transfer Injected Directly Into the Bladder Wall. U.S. National Institutes of Health.
• [17] ClinicalTrials.gov (NCT02256735) Study to Investigate the Effect of KUC 7483 CL on the QT/QTc Interval of the ECG in Comparison to Placebo and Moxifloxacin in Healthy Male and Female Volunteers. U.S.National Institutes of Health.
• [18] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018026)
• [19] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028532)
• [20] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022973)
• [21] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021639)
• [22] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022321)
• [23] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009535)
• [24] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017119)
• [25] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034728)
• [26] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020607)
• [27] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026926)
• [28] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018539)
• [29] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8586).
• [30] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [31] Role for pituitary adenylate cyclase activating polypeptide in cystitis-induced plasticity of micturition reflexes.Am J Physiol Regul Integr Comp Physiol. 2006 Apr;290(4):R951-62. doi: 10.1152/ajpregu.00734.2005. Epub 2005 Dec 1.
• [32] Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.Eur Urol. 2020 Jan;77(1):119-128. doi: 10.1016/j.eururo.2019.09.024. Epub 2019 Oct 18.
• [33] Expression and function of bradykinin B1 and B2 receptors in normal and inflamed rat urinary bladder urothelium.J Physiol. 2005 Feb 1;562(Pt 3):859-71. doi: 10.1113/jphysiol.2004.071159. Epub 2004 Dec 2.
• [34] Effect of co-administration of two different phosphodiesterase inhibitors and a (3)-adrenoceptor agonist in an experimental model of detrusor overactivity.Eur J Pharmacol. 2018 Aug 15;833:425-431. doi: 10.1016/j.ejphar.2018.06.018. Epub 2018 Jun 18.
• [35] Differential roles of peripheral and spinal endothelin receptors in the micturition reflex in rats.J Urol. 2004 Oct;172(4 Pt 1):1533-7. doi: 10.1097/01.ju.0000139540.56916.0e.
• [36] Changes of gap junctional cell-cell communication in overactive detrusor in rats.Am J Physiol Cell Physiol. 2007 Nov;293(5):C1627-35. doi: 10.1152/ajpcell.00122.2007. Epub 2007 Sep 13.
• [37] Nerve Growth Factor Levels are Associated with Overactive Bladder Symptoms and Long-Term Treatment Outcome after Transurethral Resection of the Prostate in Patients with Benign Prostatic Hyperplasia.J Urol. 2018 Sep;200(3):620-625. doi: 10.1016/j.juro.2018.03.130. Epub 2018 Apr 7.
• [38] Afferent Pathway-Mediated Effect of 1 Adrenergic Antagonist, Tamsulosin, on the Neurogenic Bladder After Spinal Cord Injury.Int Neurourol J. 2017 Sep;21(3):178-188. doi: 10.5213/inj.1734984.492. Epub 2017 Sep 12.
• [39] Changes of neuregulin-1 (NRG-1) expression in a rat model of overactive bladder induced by partial urethral obstruction: is NRG-1 a new biomarker of overactive bladder?.BMC Urol. 2013 Oct 23;13:54. doi: 10.1186/1471-2490-13-54.
• [40] Antagonism of the transient receptor potential ankyrin 1 (TRPA1) attenuates hyperalgesia and urinary bladder overactivity in cyclophosphamide-induced haemorrhagic cystitis.Chem Biol Interact. 2013 Apr 25;203(2):440-7. doi: 10.1016/j.cbi.2013.03.008. Epub 2013 Mar 21.
• [41] Suo Quan Wan Protects Mouse From Early Diabetic Bladder Dysfunction by Mediating Motor Protein Myosin Va and Transporter Protein SLC17A9.Front Pharmacol. 2019 May 24;10:552. doi: 10.3389/fphar.2019.00552. eCollection 2019.
• [42] Prevalence and clinical characteristics of overactive bladder in systemic sclerosis.Mod Rheumatol. 2020 Mar;30(2):327-331. doi: 10.1080/14397595.2019.1589913. Epub 2019 Apr 1.
• [43] Comparison of inflammatory urine markers in patients with interstitial cystitis and overactive bladder.Int Urogynecol J. 2018 Jul;29(7):961-966. doi: 10.1007/s00192-017-3547-5. Epub 2018 Jan 25.
• [44] THC/CBD oromucosal spray in patients with multiple sclerosis overactive bladder: a pilot prospective study.Neurol Sci. 2018 Jan;39(1):97-102. doi: 10.1007/s10072-017-3148-6. Epub 2017 Oct 19.
• [45] Relation of ADRB3, GEF, ROCK2 gene polymorphisms to clinical findings in overactive bladder.World J Urol. 2020 Oct;38(10):2571-2575. doi: 10.1007/s00345-019-03046-5. Epub 2019 Dec 4.
• [46] Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline Amendment 2019.J Urol. 2019 Sep;202(3):558-563. doi: 10.1097/JU.0000000000000309. Epub 2019 Aug 8.